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ABSTRACT 
 
 
 
DIVERGENT ROLES OF PI3K AND AKT IN 
RAPAMYCIN-INDUCED CARDIOPROTECTION 
AGAINST ISCHEMIA-REPERFUSION INJURY 
 
 
By Shivani K. Desai, B.S. 
 
A thesis submitted in partial fulfillment of the requirement for the degree of Masters of 
Science in Physiology at Virginia, Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2007 
 
 Major Director:  Dr. Rakesh C. Kukreja, Ph.D.  
VCU School of Medicine 
Division of Cardiology 
 
 
Coronary heart disease (CHD) is one of the leading causes of death every year 
with nearly three-fourths of all deaths caused by the disease. The challenge scientists are 
facing today is discovering new drugs to protect the heart against cellular damage caused 
by ischemia-reperfusion injury (I-R injury). Rapamycin is one such drug that has been 
shown to protect the heart against ischemia-induced cellular injury. Rapamycin 
  
x
(sirolimus) inhibits protein synthesis through inhibition of the mammalian target of 
rapamycin (mTOR). This property of rapamycin has led to its current clinical 
applications in drug-eluting stents and in immunosuppresive treatment to organ transplant 
patients. The mechanism by which this drug protects against I-R injury is currently 
unknown. The goal of this study is to elucidate rapamycin’s cardioprotective signaling 
pathway. We hypothesized that upregulation of Akt occurs possibly as part of a positive 
feedback mechanism following the inhibition of mTOR by rapamycin. Adult male ICR 
mice were treated with rapamycin (0.25 mg/kg, i.p.), or volume-matched DMSO (solvent 
for rapamycin), or rapamycin (0.25mg/kg, i.p.) plus wortmannin (WTN, 15µg/kg, i.p.), 
an inhibitor of phosphatidylinositol 3-kinase, or wortmannin alone (15µg/kg, i.p.). After 
30 min of stabilization, the hearts were subjected to 20 minutes of global ischemia and 30 
minutes of reperfusion in Langendorff model. In a separate series of experiments mice 
were either injected with DMSO or rapamycin for 30 minutes, 1 hour, and 2 hours before 
harvesting the hearts for Western blot analysis of levels of total or phosphorylated Akt at 
Ser473. Our results showed that rapamycin protected the heart as observed by a reduction 
in infarct size from 33.8 ± 2.0% in DMSO-treated hearts to 19.3 ± 4.1% in rapamycin- 
treated hearts; a 43% reduction. This infarct-limiting effect was completely blocked by 
wortmannin (29.3 ± 4.8%). However, Western blot analysis showed no change in the 
level of Akt phosphorylation after administration of rapamycin. Our current results 
further confirmed rapamycin as a potential cardio-therapeutic drug to limit infarct size, 
potentially through the PI3K signaling pathway. However, the exact signaling pathway of 
this protection still remains elusive.  
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INTRODUCTION 
 
 
 
1.1  Coronary Heart Disease 
 
 In 2004, the American Heart Association determined coronary heart disease 
(CHD), the cause of heart attacks and angina, to be the single leading cause of death in 
America. About 325,000 people a year die of CHD which is nearly 75% of all deaths. All 
in all, that is nearly 900 Americans each day, most of whom die from sudden cardiac 
arrest. Acute coronary occlusion is expected to be the major cause of death by the year 
2020 according to the World Health Organization (19; 60). With this meek prediction, 
new medical therapies are urgently needed to deal with the consequences of CHD in 
order to reduce the global impact of this disease.  
 As mentioned, CHD is the cause of heart attacks or myocardial infarctions which 
occur when there is a sudden occlusion of one or more of the coronary arteries. This 
blockage reduces or eliminates the flow of oxygenated blood to the myocardium 
normally supplied by the occluded vessel. Myocardial infarctions are usually caused by a 
condition called atherosclerosis, a buildup of cholesterol and fibrous tissue in the form of 
plaques on artery walls. The plaques may rupture the artery, causing a blood clot or 
thrombus to form and block the artery. The lack of blood flow and oxygen is called 
ischemia and if maintained for more than a few minutes, an ischemic cascade is triggered 
in which myocytes suffer permanent damage and die mainly through necrosis. As the 
division of surrounding myocytes cannot replace these dead myocytes, the
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preservation of myocardium’s viability after ischemia has become a major target for 
therapeutic research (60). 
 
1.2  Reperfusion injury 
 In an effort to find a therapy to limit infarct size, in 1983 Jennings and Reimer 
demonstrated that reperfusion of the occluded vessels was essential to protecting the 
ischemic myocardium (21). Thereafter, therapies such as thrombolysis (19), anti-platelet 
therapy (22) and primary angioplasty (19; 32) were used in the clinical setting to re-
establish coronary blood flow. Paradoxically, reperfusion therapy itself results in 
cardiomyocyte death, an inherent phenomenon termed reperfusion injury.  
 Reperfusion injury causes rapid disruption of heart tissue as shown by the release 
of cytosolic enzymes and changes in the microscopic structure of the myocytes. Two 
forms of cell death have been implicated with reperfusion (17). Studies have identified 
necrosis as one of these forms of cell death, involving tissue edema, matrix degradation, 
cell lysis and fragmentation, and inflammation (1; 19; 54). Reperfusion also produces a 
burst of free radical oxidative species and calcium overload (3), which contributes to 
necrosis (54). Apoptotic cell death is also either triggered or exacerbated during 
reperfusion (1). This finding is supported by the fact that apoptosis is an ATP-dependent 
process and diminished ATP levels due to ischemia are restored during reperfusion (19). 
Although the restoration of blood flow was an important area of investigation, in order to 
reduce infarct size, discovering new means of cell protection became one of the focused 
topics in cardiovascular research.  
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1.3  Ischemic preconditioning 
Knowledge about ischemia-reperfusion injury until the mid-1980s had led 
scientists to believe that a brief period of ischemia sublethally injured the myocardium 
and made it more sensitive to subsequent periods of ischemia, culminating in infarction. 
Then, in 1986, Murry et al. discovered that not all myocardial ischemia is harmful. The 
phenomenon of ischemic preconditioning (IPC) was found in which brief periods of 
ischemia actually protect the heart against subsequent prolonged ischemia (32; 36; 59; 
60). This intrinsic protection has been found to have a biphasic window: an early phase or 
classical preconditioning that last up to ~2 hours after the preconditioning stimulus 
followed a day later by a delayed phase or second window of protection (SWOP) lasting 
~3days (34; 42; 57; 60).  
By effectively reducing both necrosis (32; 59) and apoptosis within an infarcted 
heart (57), IPC increases the time available for effective reperfusion. Patients with 
unstable angina and those undergoing bypass surgery or coronary angioplasty can benefit 
from preconditioning (32). Furthermore, this phenomenon has been shown to occur in all 
species tested including man and with a very similar reduction in infarct size in all 
species (42). For these reasons, IPC has been recognized as “the strongest form of in vivo 
protection against myocardial ischemic injury other than early reperfusion” (28).  
Remarkably, the cardioprotective effects of IPC can be induced through the 
administration of exogenous pharmacological agents such as bradykinin (32; 42), 
adenosine (42), opioids (42), erythropoietin (15), acetylcholine (6; 42), and nitric oxide 
(NO) (31). Mitochondrial KATP channel openers (1; 39; 58), HMG-CoA reductase 
inhibitors such as simvastatin (23) and atorvastatin (11), phosphodiesterase 5 inhibitors 
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such as sildenafil (40), and certain volatile anesthetics including desflurane (52) and 
isoflurane (29) can also mimic IPC’s effects. These mimetics have been discovered over 
the past two decades through investigation of the diverse signaling pathways involved in 
the biochemical mechanism of IPC and allow us to prolong the short-lived effects of 
acute IPC (57).  
 
1.4  Phosphatidylinositol 3-kinase/Akt signaling pathway 
Tong et al. were the first to implicate the activation of the phosphatidylinositol 3-
kinase (PI3K)/Akt signaling pathway during IPC (55; 56). PI3K, a lipid kinase (2), has a 
vital role in mediating many cellular responses in both physiologic and pathophysiologic 
states such as cell cycle progression, differentiation, and survival (14). Stimulation of cell 
surface receptors activates PI3K, which then itself phosphorylates membrane 
phophoinositides at the D-3 position. These phospholipids act as second messengers that 
mediate the diverse cellular functions of PI3K (2; 24). One function of these second 
messengers is the activation of the serine/threonine kinase Akt, another name for which is 
protein kinase B (7). Akt contains a pleckstrin homology domain on its amino terminus 
that directly binds the phospholipid products of PI3K. As a result, Akt is recruited from 
its cytoplasmic location to the membrane where these PI3K products are located (53). 
This allows a conformational change in the PI3K products, enabling the phosphorylation 
of Akt by the phosphoinositide-dependent kinases 1 (PDK1) and PDK2 at residues Thr308 
and Ser473, respectively. Full activation of Akt is due to the phosphorylation of these two 
residues (2; 14; 24; 27). In turn, activated Akt phosphorylates a number of downstream 
targets. 
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1.5  Akt signaling effects 
 Akt is a multifunctional protein kinase with diverse downstream target effects that 
can be roughly divided into three groups: 1) anti-apoptotis/cell survival, 2) cellular 
growth and metabolism, and 3) increased translation. The cardioprotective effects of Akt 
activation have been mainly attributed to the reduction of myocardial apoptosis. Akt’s 
anti-apoptotic actions involve both cytoplasmic and nuclear compartments (7). Akt 
phosphorylates the protein BAD at Ser136 (22) which inhibits BAD’s pro-apoptotic 
activity by reducing its inhibition of the anti-apoptotic proteins, Bcl-2 and Bcl-XL (41; 53; 
57). Other targets include the forkhead transcription factors: FKHR, FKHR-L1, and 
AFX, which are all, down-regulated when Akt phosphorylates them (2; 41). For example, 
phosphorylation of FKR-L1 retains it in the cytoplasm through sequestration by 14-3-3 
proteins and prevents it from activating transcription of pro-apoptotic genes (53).  
Akt also promotes cell survival by maintaining the integrity of the outer 
mitochondrial membrane. By doing so, cytochrome c release into the cytosol is 
prevented. Normally if cytochrome c were allowed to be released into the cytosol, it 
would bind to and activate the apoptotic protease-activating factor (Apaf-1), which in 
turn cleaves and activates caspase-9, resulting in the activation of caspase-3 and caspase-
7. At this point the cells are committed to apoptosis (24; 43; 57). As for Akt target 
effectors in the nucleus, Akt activates IκB kinases that degrade the inhibitory protein 
IκB. IκB keeps the transcription factor, nuclear factor-κB (NF-κB), in the cytoplasm. 
Once released, NFκB is free to migrate to the nucleus and regulate transcriptional activity 
of inhibitor-of-apoptosis proteins (IAPs) (41; 53).  
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Akt has many other cardiovascular functions by activating proteins that regulate 
cellular proliferation, migration, and growth (41; 49). Glycogen synthase kinase 3 
(GSK3β) is a growth inhibitory protein (2) and well-defined direct target of Akt. When 
Akt phosphorylates GSK3β, it reduces its kinase activity (49), thus promoting glycogen 
synthesis (50). Past studies suggest that an increase in cardiac glycogen might increase 
resistance to cellular hypoxia during ischemia by providing a greater pool of fuel reserve 
for anaerobic glycolysis (53). 
Akt also has a key role in vascular homeostasis and angiogenesis (1; 50; 57). 
Several stimuli in endothelial cells activate the PI3K/Akt signaling axis and regulate 
endothelial cell survival, migration, and capillary-like structure formation, all important 
steps in angiogenesis. Additionally, Akt controls NO synthesis by phosphorylating 
endothelial nitric oxide synthase (eNOS), which has been associated with delayed 
preconditioning (26). An increase in NO synthesis results in regulation of cardiovascular 
homeostasis, vessel integrity, and vasomotor tone by increasing resting blood vessel 
diameter and blood flow (50). Finally, a recent study demonstrated a marked increase in 
heart size in mice expressing constitutively active Akt (49). This finding exemplifies 
Akt’s promotion of organ growth in vertebrates. Moreover, Akt’s role in angiogenesis 
implies that it must regulate this process during organ enlargement (50). 
The cardioprotective effect of Akt activation after transient ischemia (33) may 
render it a critical control point determining not only cardiomyocyte survival but, 
function as well. Oudit et al. found constitutively active Akt genes to be influential on 
myocardial contractile force although the effects were variable (41). This ultimately 
makes Akt an important target for therapy in ischemic heart disease. The time dependent 
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activation of Akt by IPC mimetics has been researched in the past. Ahmad et al. (1) and 
Wang et al. (58) tested the time-dependency of Akt phosphorylation by BMS-191095 and 
diazoxide, respectively. BMS-191095 and diazoxide are two mitoKATP channel openers 
known to protect the heart against I-R injury. It has already been shown that a variety of 
agents mimicking IPC are able to minimize I-R injury by the activation of prosurvival 
kinases. Yellon et al. demonstrated the cardioprotective effect of atorvastatin given at the 
commencement of reperfusion in the intact mouse heart and associated this protection 
with the upregulation of PI3K/Akt (11). 
 
1.6  Mammalian target of rapamycin  
A final Akt downstream target, the mammalian target of rapamycin (mTOR), is a 
289-kDa serine/threonine kinase. Akt activation of mTOR via phosphorylation (38) leads 
to an altered metabolism and increased growth mediated by changes in gene transcription 
and translation. Activated mTOR can phosphorylate and thereby inactivate the eukaryotic 
translation initiation factor called 4E-binding protein 1 (4E-BP1), resulting in increased 
protein translation (2; 3; 50). mTOR also phosphorylates and activates ribosomal protein 
70S6 kinase (p70S6K) at Thr389 (14; 18). Activated p70S6K phosphorylates ribosomal 
protein S6 which increases the translation of 5’–terminal oligopyrimidine (TOP) tract 
mRNAs, thus enhancing the synthesis of translational machinery (2; 49; 50). Like Akt, 
p70S6K also inactivates the pro-apoptotic peptide, BAD (16), by phosphorylating its 
Ser136 residue (22). These effects are crucial to cellular growth and enhancing protein 
synthesis. However, the present study centers on the inhibition of mTOR by the drug, 
rapamycin.  
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1.7  Rapamycin 
Rapamycin is a macrolide ester (38) produced by a strain of Streptomyces 
hygroscopicus which was isolated in 1975 from a soil sample collected from Rapa Nui, 
better know as Easter Island. These days, the natural product has the generic name 
sirolimus and has acquired the trademark name Rapamune® (47; 48). It was first isolated 
as an antifungal agent however, additional studies have shown the drug to have anti-
tumor and immunosuppressive effects (3; 10). Rapamycin’s clinical relevance includes 
its ability to prevent restenosis, a prevalent side-effect after angioplasty surgery that 
occurs in 30% to 60% of patients within the first six months. Because the drug is released 
locally, sirolimus-coated stents effectively reduce the rate of restenosis (41; 51). The 
antibiotic’s unique mechanism of action has caused it to pass clinical trials and is today 
approved as an immunosuppressive therapy in organ transplantation (47; 48).  
Rapamycin is known to bind with high affinity to its intracellular receptor, the 
immunophilin (2) FK506-binding protein FKBP12. This complex binds to mTOR, 
inhibiting its function and allowing dephosphorylation of p70S6K and 4E-BP1 (3; 20). 
Literature has shown results which suggest that inactivating mTOR/p70S6K may mediate 
the beneficial effects of preconditioning and several preconditioning mimetic drugs. One 
study found that the inhibition of p70S6K prevented the phosphorylation of BAD and 
blocked cell survival induced by insulin-like growth factor 1(IGF-1) (16). Another study 
demonstrated how prolonged activation of p70S6K can cause cardiac hypertrophy (46), 
suggesting that inhibiting the mTOR/p70S6K complex with rapamycin may have 
beneficial cardiovascular effects (13; 26).  
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Our lab (Khan et al.) was the first group to demonstrate the cardioprotective effect 
of rapamycin against I-R injury in the isolated mouse heart and in cardiac myocytes 
subjected to hypoxia-reoxygenation injury (13; 25). A significant reduction in infarct size 
was observed but, there was no improvement in heart function. In support of this result, 
another group discovered rapamycin’s ability to inhibit apoptosis by inhibiting 
phosphorylation of p53 which blocks the transcriptional activation of pro-apoptotic 
proteins such as Bax and the activation of the mitochondrial cell death process (5). 
The drug’s effect seems to be dose-dependent as lower doses (1 nM) blocked 
protection. In this study we used a previously reported cardioprotective dose (0.25mg/kg) 
(25). In most studies that show rapamycin to block cardioprotection, the drug is 
administered at or before reperfusion. In our previous study, rapamycin was administered 
as a pretreatment (25). All in all, drugs that inhibit mTOR such as rapamycin may have 
either beneficial or harmful effects depending on the dose and timing of administration 
(13).  
 
1.8  Present study 
The aim of this study is to understand the role of PI3K/Akt phosphorylation in the 
cardioprotection of rapamycin and better understand why the drug has varying effects. 
We hypothesize that rapamycin could possibly influence the cross-talk between the 
survival kinases whereby inhibition of mTOR may result in the upregulation of other 
prosurvial knases such as Akt. Until recently, it was thought that Akt directly 
phosphorylated its downstream target mTOR (38). Interestingly, research has proved Akt 
to remain active following treatment of rapamycin (20). This could indicate one of two 
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things: either a possible Akt-independent mechanism for mTOR phosphorylation or a 
possible positive feedback loop from rapamycin-inactivated mTOR to Akt. A study in 
2005 demonstrated that blocking the PI3K/Akt/mTOR pathway results in the partial 
reduction of the development of cardiac hypertrophy in vivo (14). In order to test the role 
of PI3K, we used wortmannin (WTN). WTN inactivates PI3Ks by covalent modification 
of the catalytic subunit p110 (41). We used our well-established Langendorff isolated 
perfused mouse heart model of global ischemia-reperfusion, which has been used 
extensively to probe the therapeutic efficacy of drugs. 
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Figure 1: PI3K/Akt signaling pathway 
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MATERIALS AND METHODS 
 
 
 
2.1 Animals 
 
Adult male ICR mice weighing 35.5 ± 1.2 g were supplied by Harlan Sprague 
Dawley Co. (Indianapolis, IN). All animal experiments were conducted under the 
guidelines on humane use and care of laboratory animals for biomedical research 
published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 
1996). The experimental protocols were approved by the Institutional Animal Care and 
Use Committee of Virginia Commonwealth University. 
 
2.2 Drugs and chemicals 
 
Rapamycin and wortmannin were purchased from Sigma-Aldrich (St. Louis, MO) 
and were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) for intraperitoneal 
injection (i.p.). Final concentrations for rapamycin and wortmannin were 5.55% and 
0.25%, respectively.  
 
2.3  Langendorff isolated heart preparation 
 
The methods for the isolated, perfused mouse heart preparation were previously  
 
described in detail (25; 59). Prior to isolating the heart, the animal was weighed and 
anesthetized. Anesthesia was prepared by mixing 0.2cc of heparin to protect the heart
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against microthrombi, 0.4cc of pentobarbital, and 0.2cc saline for 4 mice. Each mouse 
was injected intraperitoneally with 0.2cc of anesthesia, the equivalent of 100mg/kg of 
sodium pentobarbital per mouse. The chest was then opened at the sternum, and the heart 
was rapidly removed from the thorax and placed in a small dish containing ice-cold 
Krebs-Henseleit (K-H) buffer and heparin (0.1cc per dish), where it was trimmed of 
excessive tissue and fat. Using an illuminated magnifier (4X), the aortic opening was 
exposed and quickly cannulated on a 20-gauge blunt needle and double loop tied using 
no. 5 surgical thread.  
The heart was then retrogradedly perfused at a constant pressure of 55 mmHg 
through the aorta in a non-recirculating Langendorff apparatus (Figure 2) with modified 
K-H buffer containing (in mM) 118 NaCl, 24 NaHCO3, 2.5 CaCl2, 4.7 KCL, 1.2 
KH2PO4, 1.2 MgSO4, 11 glucose, and 0.5 EDTA. The K-H solution was pre-filtered by a 
micro-filter (Millipore Corp.) with a pore size of 0.45µm diameter, and was continuously 
gassed with 95% O2 + 5% CO2 (pH ~ 7.4). The perfusion solution was warmed to 40ºC 
through a water-jacketed glass cylinder/heat exchanger system with a warming/cooling 
bath and automatic thermal controller (Brinkmann) and was constantly circulated by a 
varistaltic water pump (Manostat). The solution was warmed to 40ºC to compensate for 
any heat loss experienced as the buffer circulates through the Langendorff apparatus. The 
ambient temperature around the heart was also kept at 37 ± 0.2 ºC throughout the 
experiment using a 100 Watt heating lamp. A digital thermometer (VWR) continuously 
monitored the temperature around the heart. During the no-flow ischemia, K-H buffer 
was periodically applied on the heart surface to keep it moist. Hearts demonstrating 
persistent arrhythmia during the pre-ischemia period were excluded from further study. 
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2.4  Assessment of heart  function 
 
Following the start of perfusion, ventricular function was measured by a force- 
displacement transducer (Grass, Model FT03) attached to the apex of the mouse heart  
through a rigid metal hook attached to a no. 5 surgical thread. The resting tension of  
the isolated heart was adjusted to 0.3g. Ventricular developed force was continuously  
recorded with a PowerLab 8SP computerized data acquisition system (AD instruments) 
connected to the force transducer. The coronary flow was calculated by timed collection 
of the efflux perfusate at 15 minutes of stabilization (for pre-ischemia value) and again at 
15 minutes of reperfusion (for post-ischemia value). The hearts were not electronically 
paced. 
 
2.5 Experimental protocol for drug pretreatment and cardiac ischemia-reperfusion 
 
To investigate whether the cardioprotective effect of rapamycin is mediated by 
the PI3K/Akt signaling pathway, we administered wortmannin, a PI3K inhibitor, in 
addition to rapamycin and the vehicle DMSO, intraperitoneally. As diagrammed in 
Figure 3, a total of 29 mice were randomly assigned to four groups. In Group 1 (n=6), 
DMSO was administered at two different time points at two different doses.  The first 
dose was equivalent to the DMSO dilution volume for dissolving WTN (0.25% DMSO in 
saline, DMSO-W). The second dose was given an hour later and was equivalent to the 
DMSO dilution volume for dissolving rapamycin (5.55% DMSO in saline, DMSO-R). In 
Group 2 (n=8) mice received the DMSO-W dose and thirty minutes later received 
rapamycin (0.25 mg/kg). Group 3 (n=7) mice were injected with WTN (15µg/kg) and 
thirty minutes later were injected with rapamycin (0.25 mg/kg). Group 4 (n=7) was 
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treated with WTN (15µg/kg) alone. All hearts were excised and isolated 90 minutes after 
the first drug was injected. The hearts were stabilized for 30 minutes after isolation and 
subjected to zero-flow ischemia for 20 minutes followed by 30 minutes of reperfusion on 
the Langendorff apparatus.  
 
 
 
Table 1: Practical notes for drug preparation 
 
  
 
GROUP 1 
DMSO  
CONTROL 
 
DMSO-R: 50µL DMSO plus 850µL saline=0.9mL. Inject  
0.15mL of this solution into each mouse (5.55% [DMSO]).  
DMSO-W: 2.5µL DMSO plus 997.5 µL saline = 1mL. Inject 0.2mL 
of this solution into each mouse (0.25 % [DMSO]). 
 
GROUP 2 
DMSO-W 
+ RAPA 
 
DMSO-W: 2.5µL DMSO plus 997.5 µL saline = 1mL. Inject 0.2mL 
of this solution into each mouse (0.25 % [DMSO]). 
RAPA: 1mL DMSO was used to dissolve 1mg vial of rapamycin. 
50µL of this solution plus 850 µL saline =0.9mL. 0.15mL of this 
solution was injected into each mouse (5.55% [rapamycin]). 
 
GROUP 3 
WTN + RAPA 
 
WTN: 1mL DMSO was used to dissolve 1mg vial of wortmannin. 
2.5µL of this solution plus 997.5 µL saline = 1mL. Inject 0.2 mL of 
this solution into each mouse (0.25 % [WTN]). 
RAPA: 1 mL DMSO was used to dissolve 1mg vial of rapamycin. 
50µL of this solution plus 850 µL saline =0.9 mL. 0.15 mL of this 
solution was injected into each mouse (5.55% [rapamycin]). 
 
GROUP 4 
WTN 
 
WTN: 1mL DMSO was used to dissolve 1mg vial of wortmannin. 
2.5µL of this solution plus 997.5 µL saline = 1mL. Inject 0.2 mL of 
this solution into each mouse (0.25 % [WTN]). 
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Figure 3: Experiment Protocol 1 
                    
    Stabilization       Global ischemia      Reperfusion 
   GROUP 1 
    DMSO  
    Control              
 
               DMSO-W, i.p.  DMSO-R, i.p.         isolate          infarct 
                  (0.25% DMSO)           (5.5% DMSO)          heart                measurement 
 
 
                       Stabilization       Global ischemia      Reperfusion 
    GROUP 2 
    DMSO-W  
    + Rapa 
 
              DMSO-W, i.p.         Rapamycin, i.p.           isolate                                               infarct  
                     (0.25%)            (0.25 mg/kg)           heart                measurement 
 
 
                       Stabilization       Global ischemia      Reperfusion 
    GROUP 3 
    WTN +  
    Rapa 
 
             WTN, i.p.          Rapamycin, i.p.         isolate           infarct 
             (15 µg/kg)            (0.25 mg/kg)                heart                measurement 
 
      
                       Stabilization      Global ischemia      Reperfusion 
    GROUP 4          
    WTN only 
 
 
      WTN, i.p.                        isolate          infarct 
                     (15 µg/kg)             heart                measuremen
1 hour 30 min 30 min  
1 hour 30 min 30 min 
20 min 30 min 
20 min 30 min 
30 min 30 min 30 min 1 hour 20 min 
20 min 1 hour 30 min 30 min 30 min 
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2.6  Measurement of infarct size 
 
 At the end of each experiment, the hearts were immediately removed from the 
Langendorff apparatus, dried with a Kimwipe, weighed, and frozen at -20°C. The next 
day, the frozen hearts were cut by hand using a surgical blade parallel to the 
atrioventricular groove, into 6 to 8 transverse slices of approximately equal thickness 
(~1mm). The slices were placed onto an inverted petri dish (Becton Dickinson Labware) 
and put face down into the inverted cover of the same petri dish. The heart slices were 
stained by incubating them in 10% 2, 3, 5-triphenyl tetrazolium chloride (TTC, Sigma) 
solution for 30 minutes at room temperature (~22°C).  
In normal myocardium, TTC is converted by dehydrogenase enzyme to a dark red 
formazan pigment. On the other hand, infracted myocardium, due to loss of 
dehydrogenase enzyme following cell membrane ruptures, does not take up TTC stain 
and remains a pale color (58). After staining, the TTC was removed and replaced with 
10% formaldehyde for additional 2-4 hours to fix the heart slices. Thereafter, the heart 
slices were digitally imaged and total area, cavities, and infracted area were measured 
using computer morphometry (Bioquant98) to determine risk area and infarct size. The 
risk area was calculated as total ventricular area minus the area of the cavities. The infarct 
size was calculated as a percentage of the risk area. 
 
2.7  Protein extraction for Western blot analysis 
  
  A separate subset of mouse hearts was used to determine Akt phosphorylation by 
rapamycin. Twenty-four (24) mice were anesthetized with sodium pentobarbital 
(100mg/kg, i.p.) and hearts were harvested from the control, DMSO-treated or 
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rapamycin-treated groups at the different time points shown in Figure 4. Two non-treated 
mice were included as control samples. The hearts were then snap frozen in liquid 
nitrogen and immediately stored in –80°C conditions until use. Each heart sample was 
crushed using a mortar and pestle. Liquid nitrogen was added as needed during this 
process to prevent the tissue sample from defreezing. Once the sample was crushed into a 
fine powder, 1.2 mL of ice-cold lysis buffer (Pierce) [containing (in mM) 25 Tris* HCL 
pH 7.6, 150 NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS] was added to each 
sample tube and kept on ice for 30 minutes. HaltTM Protease Inhibitor Cocktail Kit 
(Pierce) and HaltTM Phosphatase Inhibitor Cocktail (Pierce) were also added to the buffer 
to protect the sample protein from degradation by endogenous proteases, serine/threonine 
phosphatases and tyrosine phosphatases (10 µL of each inhibitor per mL of RIPA buffer 
used).  
The samples were then homogenized for 3 bursts of 3 to 4 seconds with a 
Polytron homogenizer and kept on ice for an additional 15 minutes before being 
transferred to Eppendorff tubes and centrifuged at 14,000 rpm (20800g, Eppendorf 
Centrifuge 5810R) at 4°C for 10 minutes. The supernatant was separated from the pellet, 
divided up into 3 aliquots, and stored in –80°C conditions for further analysis. Protein 
content of each heart sample was determined by using 10 mg of bovine serum albumin 
(BSA, Sigma-Aldrich) in 10mL of distilled water, forming a BSA stock solution. Taking 
1 mL of the solution and adding it to 19 mL of distilled water diluted this stock solution. 
This second solution was used to establish a standard curve by adding different amounts 
of the BSA solution, water and protein assay dye (Biorad). To determine the protein 
concentration of our collected samples, 2 µl of each heart tissue sample were added to 
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798 µl of water along with 200 µl of protein assay dye before protein concentration was 
determined by performing a Bradford assay using a SmartSpecTM 3000 
spectrophotometer (Biorad). 
 
 
 
Figure 4: Experimental Protocol 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMSO (5.55%) Æ n =9 
           or  
Rapamycin (0.25mg/kg) Æ n=9
    or 
Non-treated (n=2) 
Excise hearts for Western blotting
30 min  1 hour           2 hours 
 (n=3)  (n=3)              (n=3) 
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2.8  Western blot analysis for Akt 
Western blot analysis was performed to determine the effect of rapamycin and its 
vehicle, DMSO at different post-treatment time points on total Akt and phosphorylated 
Akt. Protein samples were combined with an equal volume of a loading buffer solution 
made by mixing 25 µl of Laemmli sample buffer (Biorad) and 475 µl 2-mercaptoethanol 
electrophoresis purity agent (Biorad). The samples were boiled for 7-10 minutes and 
centrifuged for 20 seconds at 14,000 rpm at room temperature before being loaded into 
each well on 10% polyacrylamide gels (Biorad). A protein marker (Biorad) was also used 
for better identifying the molecular weight of the target protein. The gels were 
electrophoresed by a Biorad energy pack for 1 hour at 180 volts using a running buffer 
[1X Tris/glycine/SDS (TGS)]. These electrophoresed proteins were transferred from the 
gel to nitrocellulose membranes (Biorad) for 90 minutes at 400 mA in 4°C using a 
transfer buffer (700 mL water, 200 mL methanol, 100 ml 10X TGS). After transfer, the 
nitrocellulose membranes were washed for 5 minutes using 1X Tris-buffered saline 
(Biorad) and 5% Tween-20 (Biorad) wash (TBST). The membranes were incubated for 1 
hour in 20 mL of a blocking solution [5% blotting milk (Biorad), 20 mL of TBST] at 
room temperature to block nonspecific binding sites. Subsequently, the membranes were 
incubated with a goat polyclonal antibody (Santa Cruz) specific for total Akt or a rabbit 
polyclonal antibody (Santa Cruz) specific for phosphorylated Akt each in 1:1000 
dilutions (i.e. 20 µl antibody in 20 mL of blocking solution) on a rocking platform 
overnight in a 4°C cold room. The housekeeping gene, β-actin (Santa Cruz), was also 
blotted to demonstrate the protein loading condition in each gel lane.  
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The next day, the blots were washed thoroughly with approximately 15 mL of 
TBST three times for 7-10 minutes each. The blots were then incubated in 1:1000 
dilutions of horseradish-labeled anti-goat secondary antibody (Santa Cruz) and anti-rabbit 
secondary antibody (Amersham) in 20 mL of blocking buffer for 2 hours at room 
temperature. After a thorough wash with TBST again three times for 7-10 minutes each, 
the blots were exposed to enhanced chemiluminescence (ECL, Amersham) for a few 
seconds, wrapped in plastic wrap and taped down in a developing cassette. In a dark 
room, each membrane was exposed to film for approximately one minute for total Akt 
and phosphorylated Akt and 20-30 minutes for β-actin before being developed by a film 
processor (Kodak). The bands of proteins were visualized and quantified using the Image 
J (Image Processing and Analysis in Java) computer program.  
 
2.9  Data analysis and statistics 
 
The difference between groups was analyzed by unpaired t-tests. P < 0.05 was 
considered to be statistically significant. All values are expressed as means ± SEM.
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RESULTS 
 
 
 
3.1 Exclusions 
 
A total of 33 mice were used in the isolated perfused heart study and were used 
for data analysis. Among these, 4 hearts (12% of the 33 perfused hearts) were excluded 
from various experimental groups due to one or more of the following reasons: damage 
of the aorta during cannulation, excessive coronary flow (>6 mL/min), longer cannulation 
time (>3 min), arrhythmic heart beat during the equilibration period.  Twenty-four mice 
were used for Western blot analysis and no mice were excluded from this experiment. 
 
 
Table 2: Morphometric characters of mice used in isolated heart 
experiment 
 
 
 
Values shown as means ± standard error of mean (SEM). 
 
 
Experimental Groups  
 
Body weight (g) Heart Wet Weight (mg) 
 
 
DMSO (n=6) 33.5 ± 3.5 237 ± 15 
   
RAPA (n=8) 38.6 ± 3.5 230 ± 11 
   
WTN+RAPA (n=7) 34.7 ± 0.8 203 ± 6 
   
WTN (n=7) 36.8 ± 0.6 221 ± 9 
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3.2  Rapamycin preconditioning reduced infarct size 
 
 Previously, rapamycin has been shown to have a cardioprotective effect in the 
isolated mouse heart model. This was demonstrated by a reduction in infarct size in 
rapamycin-treated mice (25). As shown in Figure 5A, the infarct size in DMSO control 
mice was 33.8 ± 2.0% of risk area. As targeted, rapamycin significantly (P=0.0149) 
decreased infarct size to 19.3 ± 4.1%, a 43% reduction compared to the DMSO control 
group. Infarct size was calculated as a percentage of total risk area, a measured area that 
did not vary among the four experimental groups (Figure 5B). This degree of protection 
by rapamycin is comparable to the highly selective mitochondrial KATP channel opener, 
diazoxide (54% decrease). Like rapamycin, diazoxide reduced infarct size from 27.8 ± 
4.2% to 12.9 ± 1.2% after pharmacological preconditioning with diazoxide (39). 
 
3.3  Wortmannin blocked rapamycin protection 
 
Wortmannin has been used effectively in past studies as a specific PI3K inhibitor 
(44), blocking signaling to all downstream effectors including Akt (11). To verify the 
potential Akt mediation of rapamycin protection, wortmannin was used to block PI3K 
and therefore all proteins downstream including Akt. Figure 5A illustrates the similarity 
in infarct size between the DMSO control and Group 3 mice which were treated with 
wortmannin and rapamycin (29.3 ± 4.8%). As predicted, wortmannin effectively 
abrogated rapamycin-mediated cardioprotection.  
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3.4  Wortmannin alone protected the heart 
 
Interestingly, there was a significant (P=0.0403) reduction in infarct size (24.7 ± 
3.2%) in the group treated solely with wortmannin (Figure 5A). This result suggests that 
wortmannin may have cardioprotective capabilities against I-R injury. 
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Figure 5A: Myocardial infarct size 
Mice were divided into 4 groups and hearts were isolated and perfused as
described in chapters 2.3 and 2.5. Infarct size was significantly reduced in two
different groups, RAPA-treated and WTN-treated mice (*P<0.05 vs. DMSO).
Wortmannin also proved to effectively block rapamycin protection. 
 
Figure 5B:  Risk area  
Risk area was calculated as a percentage of total area and was similar in all
four experimental groups. 
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Figure 6: Representative digital images of stained heart slices  
  A) DMSO-treated heart (n=6) 
  B) RAPA-treated heart (n=8) 
  C) WTN- and RAPA-treated heart (n=7) 
  D) WTN-treated heart (n=7) 
 
Heart slices were stained with TTC and fixed with formalin. Viable
tissue remains red, whereas infarcted tissue appears pale and colorless. 
The DMSO control heart (A) has much larger infarcted area as compared
to the RAPA-treated heart (B), showing healthy myocardium and little
infarcted tissue.  The same can be said of WTN-treated hearts (D) which 
show very little pale tissue. On the other hand, the group treated with
WTN and RAPA (C) has a measurable amount of dead tissue which
suggests that WTN successfully blocked rapamycin-induced protection. 
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3.5  Cardiovascular function 
Pre-ischemic and post-reperfusion values of hemodynamic and cardiovascular 
function of the isolated perfused hearts are summarized in Table 2. In order to study the 
effect of rapamycin on heart function as well as infarct size we used the isolated heart 
model, eliminating the influence of circulating factors on the heart. Rate-force product 
(RFP) is a measured estimation of cardiac function and is calculated as developed force x 
heart rate (g x beats/minute). When RFP was calculated as a percentage of baseline pre-
ischemia values, there was no significant change between all four experimental groups 
(Figure 7). However, observation of the individual RFP values in Table 2 shows a 
significant decrease in RAPA-treated groups post-reperfusion compared to DMSO-
treated groups post-reperfusion (P=0.0099).  
 
Figure 8 shows a significant decrease in developed force (DF) post-reperfusion, 
between mice treated with DMSO and those treated with RAPA (P= 0.0268). DF is the 
amplitude of heart contractility independent of heart rate. A constant trend of reduced DF 
after ischemia can be observed in all the experimental groups. 
 
Coronary effluent was measured for one minute after 15 minutes of stabilization 
and again 15 minutes after reperfusion as an estimation of coronary flow in vivo. There 
was no significant change in coronary flow from the pre-ischemic baseline measurement 
to the post-reperfusion measurement in RAPA-treated mice due to variability within this 
group (Figure 9B). Nevertheless, there is a noticeable increase in coronary flow in the 
RAPA-treated group compared to the DMSO-treated group during both pre-ischemia and
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post-reperfusion (Figure 9A). An unexpected result, illustrated in Figure 9A, is a 
significant elevation of coronary flow in WTN-treated groups, pre-ischemia (P= 0.05) 
and post-reperfusion (P= 0.0414) compared to the DMSO control group. This result adds 
to and explains the increased RFP in WTN-treated groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2: Values of hemodynamic and contractile parameters of isolated perfused hearts after 15 minutes of 
stabilization (pre-ischemia) and after 30 minutes of reperfusion 
 
 
                                
                                 Pre-ischemia                                     At 30 minutes of reperfusion 
 
 DMSO RAPA WTN+RAPA WTN DMSO RAPA WTN+RAPA WTN 
         
HR (beats/min) 321 ± 29 350 ± 22 359 ± 32 350 ± 16 350 ± 27 325 ± 36 396 ± 28 358 ± 12 
DF (g) 0.82 ± 0.14 0.61 ± 0.12 0.56 ± 0.20 0.76 ± 0.16 0.67 ± 0.10 0.36 ± 0.07 a  0.50 ± 0.20 0.55 ± 0.16 
RFP(g beats/min) 278 ± 67 214 ± 44 171 ± 48 258 ± 48 231 ± 31 108 ± 22 b  178 ± 67 189 ± 49 
CF (mL/min) 1.38 ± 0.13 2.39 ± 0.52 1.86 ± 0.46 1.81 ± 0.15 c 1.29 ± 0.09 3.02 ± 0.89 1.71 ± 0.45   1.83 ± 0.20d
  
 
 a P  < 0.05 vs. DMSO post-reperfusion (unpaired t test) 
 b P <0.05 vs. DMSO post-reperfusion (unpaired t test) 
 c P  <0.05 vs. DMSO pre-ischemia (unpaired t test) 
 d P <0.05 vs. DMSO post-reperfusion (unpaired t test) 
 
HR, heart rate; DF, developed force; RFP, rate-force product; CF, coronary flow. Values shown are means ± SEM. Experimental groups: 1)  DMSO = 
mice treated with vehicle control (0.25% DMSO, i.p.) 90 min and 30 min (5.5% DMSO, i.p.) prior to ischemia-reperfusion (I-R);   2) RAPA = mice treated with 
vehicle 90 min (0.25% DMSO, i.p.) before I-R and with rapamycin (RAPA, 0.25mg/kg, i.p.) 30 min prior to I-R;   3)  WTN + RAPA = mice treated with 
wortmannin (WTN, 15µg/kg, i.p.) 90 min prior to IR and with RAPA (0.25mg/kg, i.p.) 30 min prior to IR;    4)  WTN = mice treated with WTN (15µg/kg, i.p) 
90 min prior to I-R.   30 
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Figure 7: Rate-force product 
There was no significant difference in the recovery of cardiac
function (rate-force product) among groups. Rate-force product 
was taken as a percentage of the pre-ischemia baseline value. 
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Figure 8: Developed force 
Post reperfusion, a significant difference in developed force was 
observed between DMSO-treated and RAPA-treated groups
(*P<0.05). 
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Figure 9A:  Coronary flow 
Mean coronary flow pre-ischemia (after 15 min stabilization and 
post-reperfusion (after 15 min of reperfusion). There was no 
significant difference in coronary flow among the groups, pre-
ischemia or post-ischemia except in the group treated with WTN. 
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Figure 9B: Percent change of coronary flow 
The percent change of coronary flow was calculated from the pre-
ischemia baseline to post-reperfusion. There was no significant 
difference in the change in coronary flow from baseline to
reperfusion among the groups. However, a marked difference can 
be noted between DMSO- and RAPA-treated groups.  
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3.5  Western blot analysis of Akt 
 
IPC protects the heart by phosphorylating the prosurvival kinase, Akt (4). Mice 
were pharmacologically preconditioned with the DMSO (n=3) and rapamycin (n=3).  
Hearts were then harvested after 30 minutes, 1 hour, and 2 hours of pretreatment. The 
phosphorylation state of Akt in the prosurvival pathway was then examined via Western 
blot analysis. Hearts in a non-treated control group (n=2) were also blotted for changes in 
phosphorylation of Akt at Ser473, although the DMSO-treated group was considered as the 
true control group as DMSO was used as the vehicle for rapamycin administration. 
Representative western blots are displayed in Figure 10. After careful densitometry 
measurement of completed Western blots, no appreciable difference in the 
phosphorylation state of Akt versus total Akt was observed between any of the time 
points or experimental groups (Figure 11). Total Akt was also blotted for although these 
protein levels did not vary, suggesting that any changes in kinase phosphorylation were 
not due to changes in total kinase levels. All in all Western blot analysis did not confirm 
any change in Akt phosphorylation.  
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Figure 10: Western blot analysis of Akt 
This analysis was performed in triplicate for DMSO- and
RAPA-treated groups (A, B, C). Each Western blot is
shown as a pair with phosphorylated Akt Ser473 (top) and
total Akt (bottom). 
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Figure 11: Western blot densitometry 
Measurements were calculated as a ratio of phosphorylated Akt to
total Akt which are similar among all groups and time points. The
phosphorylation state of Akt was compared with densitometric
analysis by the Image J software program. Bar graphs represent the
mean ± SEM. 
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DISCUSSION 
 
 
 
4.1  Present study 
 
The concept that pharmacological preconditioning with rapamycin protects the 
heart against I-R injury was first introduced by Khan et al. in 2006 from our laboratory 
(25). However, the cellular and molecular mechanism that mediates this protection 
remains elusive. The aim of this study was to define the signaling mechanisms underlying 
the cardioprotective action of rapamycin. We postulated that Akt mediates rapamycin-
induced protection via a positive feedback loop to Akt from mTOR, which is inhibited by 
rapamycin. We were particularly interested in studying the role of Akt because this 
signaling molecule has been shown to be activated by IPC (18; 26) and by IPC mimetics 
such as insulin (22) which initiate the PI3K/Akt prosurvial signaling cascade. In these 
studies, cardioprotection is induced through mTOR and p70S6K activation, resulting in 
an increase in translation and protein synthesis. 
 
4.2  Rapamycin-induced cardioprotection 
 
 In the current investigation, mice were pre-treated with rapamycin (0.25mg/kg) 
after which hearts were subjected to ischemia and reperfusion in the isolated perfused 
heart model. The rationale for using the isolated heart model was to eliminate all 
circulating factors that exist in vivo and demonstrate the direct effect of rapamycin on the
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post-ischemic recovery of function and infarct size in the intact heart. Our results show 
that rapamycin significantly reduced infarct size as compared to DMSO-treated control 
hearts. However, there was no improvement in the recovery of heart function or 
developed force (heart contractility), which essentially confirms the data from our 
previous study (25). Contrarily, we observed an increase in coronary flow in rapamycin-
treated mice before ischemia and after reperfusion, which indicates a possible 
vasodilating property of rapamycin.  
Rapamycin is a well-known inhibitor of mTOR and is usually used to block 
signaling in the prosurvival pathway, which abolishes cardioprotection (16; 22). This 
property of rapamycin presents a challenge in explaining why the current study 
contradicts precedent research. First, the inhibition of mTOR by rapamycin results in 
decreased protein synthesis, one of the highest ATP-consuming cellular processes. This 
could potentially direct more of the cell’s energy reserve and resources to protecting the 
heart against ATP-depletion during ischemia. In accordance with this concept, Granville 
et al. showed that inhibition of mitochondrial protein synthesis with chloramphenicol in 
isolated perfused rat hearts reduced infarct size (12). Protection may also be animal 
model specific, but little additional research has been done with rapamycin and the 
isolated perfused mouse model to prove this conclusion. 
 
4.3 Rapamycin-induced cardioprotection is PI3K-dependent and wortmannin alone leads 
cardioprotection  
 
In the present study, wortmannin blocked cardioprotection conferred by 
rapamycin as demonstrated by a similar degree of infarct size as the DMSO control 
group. This suggests that PI3K is involved in mediating rapamycin-induced signaling. An 
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unexpected yet tentative finding in the current study was that wortmannin alone conferred 
protection in the heart against ischemia-reperfusion as demonstrated by a significant 
decrease in infarct size (compared to the DMSO control group). The exact mechanism of 
this protection is not clear although it can be explained by known actions of wortmannin. 
As a potent and widely used PI3K inhibitor (44), wortmannin blocks all downstream 
signaling targets of this protein. For example, it has been previously shown that 
wortmannin directly inhibits signaling functions of mTOR by irreversibly inhibiting its 
autokinase activity (4). Moreover, varying levels of mTOR activation in a lymphoma cell 
line was associated with different concentrations of wortmannin treatment. The mTOR 
signaling was attenuated when cells were exposed to sub- or low- micromolar 
concentrations of wortmannin (4). Because of the attenuated mTOR signaling as a result 
of wortmannin treatment, there may be reduced protein synthesis similar to rapamycin 
treatment, which could potentially lead to more focused activation of cell survival 
machinery.  
Also, the specificity of wortmannin solely as a PI3K inhibitor must be questioned. 
Research by Davies et al. demonstrated wortmannin inhibition of other members of the 
PI3K superfamily in addition to PI3K itself (9). Wortmannin was found to be an inhibitor 
of SmLCK or smooth muscle myosin light chain kinase (37), although to a lesser degree 
than PI3K. Wortmannin also inhibited GSK3β also to a significant yet lesser degree than 
PI3K (8). Thus the protection against ischemia-reperfusion by wortmannin observed in 
the present study could by an inadvertent result of the inhibition of other kinases besides 
PI3K.  
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Lastly, the Ras-Raf-MEK-Erk signaling cascade has been shown to be inhibited 
by the PI3K/Akt signaling cascade with specific cross-talk between Akt inhibiting Raf-1 
(Figure 12) (35; 45). When PI3K was blocked by wortmannin, Akt signaling was blocked 
as well, including inhibition of Raf-1. This could have liberated the Ras-Raf-MEK-Erk 
pathway to confer cardioprotection. Although there is no clear evidence available in the 
literature about the role of wortmannin as being cardioprotective, this leaves an area of 
research open to further studies. 
 
4.4   Akt not upregulated by rapamycin 
 
Previous studies have shown increased Akt phosphorylation after IPC. The 
overexpression of constitutively active Akt was discovered to reduce infarct size and 
apoptosis (26). Also, Li et al. reported that rapamycin significantly increased Akt 
phosphorylation in cardiomyocytes (30). Because of the anti-necrotic and anti-apoptotic 
effect of rapamycin in adult cardiomyocytes (25), we postulated that the drug may exert 
such cardioprotective effects through upregulation of Akt. In the present study, we 
monitored phosphorylation of Akt following treatment with rapamycin. Surprisingly, Akt 
was not phosphorylated significantly in both DMSO control and rapamycin-treated 
hearts. We evaluated the phosphorylation states of Akt at Ser 473 after 30 minutes, 1 hour 
and 2 hours following rapamycin treatment in order to carefully track the phosphorylation 
time-course of this signaling molecule. Therefore, it is unlikely that this treatment 
protocol might have missed the transient activation of Akt unless it occurred in less than 
30 minutes after treatment with rapamycin. Another possibility is that Akt may not be 
upregulated at all by rapamycin without an ischemic trigger.  
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Finally, as mentioned earlier there is a possibility that Akt may work in concert 
with Erk in a parallel pathway to reach the “threshold” of mTOR or p70S6K 
inactivation/activation by rapamycin. Hausenloy et al. originally reported that, the 
PI3K/Akt and MEK-Erk signaling cascades exhibit cross-talk when they are activated by 
IPC. When Akt signaling was inhibited by the PI3K inhibitor LY294002, Erk in the other 
cascade pathway was activated. In turn, Akt was activated when PD98059 was used to 
inhibit the MEK-Erk pathway (17-19). In response to I-R injury, these kinase cascades 
activate protection through their anti-apoptotic effectors. Erk activation was also shown 
to be insensitive to inhibitors of PI3K such as wortmannin (9). Further evaluation on the 
effect of rapamycin on phosphorylation of Erk and MEK are needed to support this 
argument. 
It is also possible that rapamycin might have another intracellular target that 
mediates its cardioprotection besides mTOR. Because wortmannin blocked rapamycin 
protection and Akt phosphorylation was not influenced by rapamycin, it can be implied 
that PI3K is involved in mediating signaling and not necessarily Akt. Hypothetically, 
rapamycin could directly target PI3K and whatever lies downstream of PI3K other than 
Akt for example, through a PDK1-PKC-dependent pathway. As a result, PI3K might 
have a direct signaling link to the Ras-Raf-MEK-Erk pathway. Rapamycin is known to 
inhibit mTOR and attenuate protein synthesis leaving more energy for prosurvival. 
Contrary to our previous hypothesis of a feedback loop between mTOR and Akt, there 
may be a signaling loop between mTOR and PI3K instead (see Figure 12). 
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4.5  Future studies 
Obviously, more thorough investigations are required to demonstrate the effect of 
rapamycin on Akt phosphorylation. This will be accomplished by monitoring Akt 
phosphorylation on hearts preconditioned with rapamycin and subjected to ischemia-
reperfusion in the isolated perfused heart model. In the present investigation, we were 
interested in studying the role of rapamycin in Akt phosphorylation without the 
confounding effect of ischemia-reperfusion. Other kinases in PI3K/Akt must also be 
blotted for such as PDK1, mTOR, and p70S6K along with kinases in the prosurvival 
pathways such as Erk and Raf also need to be investigated to see if they have a role in 
cardioprotection with rapamycin. 
 
4.6  Conclusions 
 
Although preventive medicine will most effectively control the prevalence of 
heart disease and myocardial infarctions, limitations such as the expenses and availability 
of medicine impairs this approach. Novel medical treatments that will limit the extent of 
damage caused by a myocardial infarction are urgently needed. Cellular protection or 
tolerance against ischemia is coming to the forefront of research in order to find new 
methods for treating cardiovascular diseases. This study acknowledges rapamycin as an 
important pharmacological agent that protects the heart against I-R injury. To our 
knowledge this is the first study implicating divergent roles of PI3K and Akt in the 
signaling mechanism of rapamycin-induced cardioprotection in the isolated perfused 
mouse model. Development of this model lays the groundwork for investigating other 
signaling pathways for the benefit and management of acute myocardial infarction. 
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Figure 12: Final hypothetical signaling pathway 
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